CARsgen Therapeutics (HKG:2171) expects its H1 loss to narrow year over year, according to a Hong Kong bourse filing Friday.
The cell therapies producer said it expects a loss of up to 80 million yuan for the six months ended June 30, as compared with a loss of 351 million yuan in the year-ago period.
CARsgen expects to report its financial results by the end of August.
Shares of the company were up over 1% in morning trade Friday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。